JPH10203996A5 - - Google Patents

Info

Publication number
JPH10203996A5
JPH10203996A5 JP1998005853A JP585398A JPH10203996A5 JP H10203996 A5 JPH10203996 A5 JP H10203996A5 JP 1998005853 A JP1998005853 A JP 1998005853A JP 585398 A JP585398 A JP 585398A JP H10203996 A5 JPH10203996 A5 JP H10203996A5
Authority
JP
Japan
Prior art keywords
composition
casein
energy
tgf
lipid source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998005853A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10203996A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JPH10203996A publication Critical patent/JPH10203996A/ja
Publication of JPH10203996A5 publication Critical patent/JPH10203996A5/ja
Pending legal-status Critical Current

Links

JP10005853A 1997-01-14 1998-01-14 炎症状態にある胃腸管の治療用組成物とその方法 Pending JPH10203996A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP972000962 1997-01-14
EP97200096 1997-01-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010024536A Division JP2010100655A (ja) 1997-01-14 2010-02-05 炎症状態にある胃腸管の治療用組成物とその方法

Publications (2)

Publication Number Publication Date
JPH10203996A JPH10203996A (ja) 1998-08-04
JPH10203996A5 true JPH10203996A5 (enExample) 2005-08-04

Family

ID=8227929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10005853A Pending JPH10203996A (ja) 1997-01-14 1998-01-14 炎症状態にある胃腸管の治療用組成物とその方法
JP2010024536A Withdrawn JP2010100655A (ja) 1997-01-14 2010-02-05 炎症状態にある胃腸管の治療用組成物とその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010024536A Withdrawn JP2010100655A (ja) 1997-01-14 2010-02-05 炎症状態にある胃腸管の治療用組成物とその方法

Country Status (4)

Country Link
US (1) US5952295A (enExample)
JP (2) JPH10203996A (enExample)
AU (1) AU749365B2 (enExample)
CA (1) CA2223198A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1034704A1 (en) * 1999-03-12 2000-09-13 Societe Des Produits Nestle S.A. Nutritional composition intended for specific gastro-intestinal maturation in premature mammals
US6210701B1 (en) * 1999-04-30 2001-04-03 Healthcomm International, Inc. Medical food for treating inflammation-related diseases
EP1372641A4 (en) 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
CA2444470A1 (en) * 2001-04-10 2002-10-24 Societe Des Produits Nestle S.A. Method and composition for prophylaxis of diabetes
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
EP1572115B1 (en) 2002-11-27 2015-01-21 Ampio Pharmaceuticals, Inc. Treatment of diseases and conditions mediated by increased phosphorylation
KR101277367B1 (ko) * 2003-01-31 2013-06-20 디에스엠 아이피 어셋츠 비.브이. 카로티노이드를 포함하는 조성물
AU2004219603A1 (en) * 2003-03-11 2004-09-23 Genentech, Inc. Novel compositions and methods for the treatment of immune related disease
US7875291B1 (en) 2003-09-05 2011-01-25 Glu-Pro, Inc. Composition for managing diabetes, obesity, and hyperlipidemia and associated methods
BRPI0415480B1 (pt) * 2003-10-16 2019-09-17 Nestec S.A. Composição nutricional contra efeitos colaterais de quimioterapia ou radioterapia
US7763257B2 (en) * 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
US20060127493A1 (en) * 2004-12-09 2006-06-15 Yves Pouliot Composition for treating psoriasis
US7572474B2 (en) * 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US8287931B2 (en) * 2005-06-30 2012-10-16 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
PL1800675T4 (pl) * 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
MX2010005893A (es) 2007-11-29 2011-03-04 Genentech Inc Star Marcadores de expresion genica para enfermedad inflamatoria de intestino.
US8367354B2 (en) * 2008-10-24 2013-02-05 Mead Johnson Nutrition Company Methods for determining the levels of TGF-β in a composition
US8350006B2 (en) * 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
US8986769B2 (en) * 2008-10-24 2015-03-24 Mead Johnson Nutrition Company Methods for preserving endogenous TGF-β
US8293264B2 (en) * 2009-05-11 2012-10-23 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
AU2010276392A1 (en) 2009-07-20 2012-03-08 Genentech, Inc. Gene expression markers for Crohn's disease
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
US20120171328A1 (en) * 2011-01-05 2012-07-05 Dattatreya Banavara Composition comprising heat labile milk proteins and process for preparing same
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
BR112015001884B1 (pt) * 2012-07-31 2020-12-01 Société des Produits Nestlé S.A. composição nutricional para promover a saúde musculoesquelética em pacientes com doença inflamatória intestinal (ibd), seu uso, e formulação farmacêutica, formulação nutricional, formulação de alimentação por tubo, suplemento alimentar, alimento funcional ou produto de bebida
PL3212198T3 (pl) 2014-10-29 2021-08-23 Glycom A/S Syntetyczna kompozycja i sposób promowania gojenia się błony śluzowej
IT201900008394A1 (it) * 2019-06-07 2020-12-07 Sofar Spa Composizione per uso nel trattamento delle malattie infiammatorie croniche intestinali

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60203172A (ja) * 1984-03-29 1985-10-14 Sanwa Kagaku Kenkyusho:Kk 経口・経管栄養食
GB8723094D0 (en) * 1987-10-01 1987-11-04 Ciba Geigy Ag Polypeptide growth factor from milk
JP3102645B2 (ja) * 1990-10-15 2000-10-23 雪印乳業株式会社 栄養補給用栄養組成物
DK0527283T3 (da) * 1991-08-12 1998-08-10 Nestle Sa Levnedsmiddelsammensætning
US5661123A (en) * 1995-01-17 1997-08-26 Nestec, Ltd. Enteral composition for malabsorbing patients

Similar Documents

Publication Publication Date Title
JPH10203996A5 (enExample)
RU2008130365A (ru) Питательные композиции для младенцев, предназначенные для предупреждения ожирения
DE69534128T2 (de) Verwendung von Laurinsäure oder vom einem C8-C16 Fettsäuremonoglyzerid zur Hemmung von Helicobacter
CA1261274A (en) Pharmaceutical and dietary compositions
CN1091363C (zh) 脂肪掺合物
AU727637B2 (en) Nutritional support of paediatric patients
CN101360490A (zh) 具有二十二碳五烯酸的组合物
EP1832181A3 (en) Microbial oil mixtures and uses thereof
JP2009521214A5 (enExample)
CN1099610A (zh) 用于吸烟者的制剂
RU2003107827A (ru) Пищевая композиция и способ улучшения накопления белка
CA2362271A1 (en) Essential fatty acids in the prevention of cardiovascular events
EP1662905A1 (en) Lipid system and methods of use
ATE361066T1 (de) Polyungesättigen fettsäuren nährungsergänzung
PT1216041E (pt) Dieta com elevado teor de lipidos
KR890000085A (ko) 필수지방산 합성물(Essential Fatty Acid Compositions)
Welch et al. The role of “folic acid” and biotin in the nutrition of the rat
CA2039980A1 (en) Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients
ZA971134B (en) Multifunctional fat absorption and blood cholesterol reducing formulation.
AU2441400A (en) Stabilized lipidic composition, method for the preparation thereof and nutritional product containing the same
DE3579471D1 (de) Orales dextran enthaltende zusammensetzungen.
Das Hypothesis: cis-unsaturated fatty acids as potential anti-peptic ulcer drugs
CA1279823C (en) Pharmaceutical and dietary composition for pre-menstrual syndrome
Tsujikawa et al. Medium-chain triglyceride-rich enteral nutrition is more effective than low-fat enteral nutrition in rat colitis, but is equal in enteritis
Matsuba et al. Effect of dietary linoleate/α-linolenate balance on experimentally induced gastric injury in rats